ZOLEDRONIC ACID
Clinical safety rating: avoid
Contraindicated (not allowed)
Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway.
| Metabolism | Zoledronic acid is not metabolized and is excreted unchanged by the kidney via glomerular filtration and tubular secretion. |
| Excretion | Primarily renal (30-40% unchanged in urine over 24h, accounting for ~50% of total clearance); negligible biliary or fecal elimination (<1%). |
| Half-life | Terminal half-life is approximately 146 hours (6 days), reflecting slow release from bone; clinical effect persists beyond this due to prolonged binding to hydroxyapatite. |
| Protein binding | ~28% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | 0.13 L/kg (range 0.1-0.2 L/kg), indicating limited distribution to peripheral tissues; extensive binding to bone mineral surfaces. |
| Bioavailability | Oral bioavailability is negligible (<1% due to high polarity and poor absorption); only administered intravenously. |
| Onset of Action | IV: Onset within 24-48 hours for reduction of bone resorption markers; maximal effect on serum calcium in hypercalcemia occurs within 4-7 days. |
| Duration of Action | Single dose suppresses bone resorption for up to 12 months; repeat dosing at approved intervals (e.g., annually for osteoporosis) maintains effect. |
| Molecular Weight | 290.1 |
5 mg intravenously over at least 15 minutes once yearly for Paget disease or osteoporosis; 4 mg intravenously over at least 15 minutes every 3-4 weeks for hypercalcemia of malignancy or multiple myeloma/bone metastases.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated if CrCl <35 mL/min. For CrCl 35-60 mL/min: no dose adjustment for osteoporosis; for malignancy, consider risk/benefit. CrCl <35 mL/min: use not recommended. Monitor serum creatinine before each dose. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment. Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Safety and efficacy not established in children; use only in clinical trials or specific conditions like osteogenesis imperfecta. Dosing typically 0.05-0.1 mg/kg intravenously over at least 30 min, frequency based on study protocol. Off-label use with caution. |
| Geriatric use | No specific dose adjustment based on age alone; renal function must be assessed (CrCl) and dose adjusted accordingly. Monitor for renal toxicity, hypocalcemia, and atrial fibrillation risk. |
| 1st trimester | Zoledronic acid is contraindicated in pregnancy. Animal studies show skeletal and visceral malformations, and fetal toxicity. No adequate human data. |
| 2nd trimester | Contraindicated due to potential fetal harm from bisphosphonate incorporation into bone matrix. |
| 3rd trimester | Contraindicated; risk of neonatal hypocalcemia and skeletal abnormalities. |
Clinical note
Nephrotoxic drugs may increase risk of renal impairment Can cause renal impairment and osteonecrosis of the jaw.
| Placental transfer | Zoledronic acid crosses the placenta in animals; likely in humans based on molecular weight and bisphosphonate properties. |
| Breastfeeding | Zoledronic acid is excreted in animal milk; unknown in humans. Due to potential for bone growth suppression, breastfeeding is not recommended during therapy and for a period after discontinuation. |
■ FDA Black Box Warning
Zoledronic acid is not recommended for use in patients with severe renal impairment (CrCl <35 mL/min) due to increased risk of renal failure. Acute renal failure may occur, especially in patients with pre-existing renal dysfunction or dehydration.
| Common Effects | Nausea Headache Dizziness Itching Insomnia difficulty in sleeping Rash Genital itching Vaginal inflammation Phlebitis Injection site reactions pain swelling redness |
| Serious Effects |
Hypersensitivity to zoledronic acid or any bisphosphonateHypocalcemiaSevere renal impairment (CrCl < 35 mL/min)Pregnancy
| Precautions | Renal toxicity: Monitor renal function before and during therapy; avoid in severe renal impairment (CrCl <35 mL/min)., Acute phase reaction: Transient flu-like symptoms (fever, myalgia, arthralgia) may occur, especially with first dose., Osteonecrosis of the jaw (ONJ): Risk factors include invasive dental procedures, cancer, poor oral hygiene; perform dental exam before treatment., Atypical femur fractures: Subtrochanteric and diaphyseal fractures reported; evaluate if thigh or groin pain occurs., Hypocalcemia: Correct hypocalcemia and vitamin D deficiency before initiating therapy; monitor calcium levels., Severe bone, joint, and muscle pain: May occur; consider discontinuation if symptoms persist. |
Loading safety data…
| Lactation Rating | L5 |
| Teratogenic Risk | Zoledronic acid is pregnancy category D. First trimester: Potential for skeletal abnormalities based on animal studies. Second and third trimesters: Risk of fetal hypocalcemia and skeletal retardation due to placental transfer and bone remodeling inhibition. Avoid use unless benefit outweighs risk. |
| Fetal Monitoring | Monitor serum calcium, magnesium, phosphate, and creatinine in mother. Fetal ultrasound for skeletal development if exposure occurs. Neonatal monitoring for hypocalcemia and electrolyte disturbances. |
| Fertility Effects | Zoledronic acid may impair fertility in males and females based on animal studies (reduced fertility and fetal loss). Clinical data in humans limited; consider potential for ovarian or testicular toxicity. |
| Food/Dietary | No specific food interactions. However, patients should avoid high-calcium foods within 30 minutes of taking calcium supplements? No direct interaction with food. Avoid alcohol? No specific warning. Maintain adequate calcium intake from diet or supplements as prescribed. |
| Clinical Pearls | Monitor serum creatinine before each dose; do not administer if CrCl <35 mL/min. Assess for hypocalcemia before initiation; ensure adequate calcium and vitamin D intake. Acute phase reaction (flu-like symptoms) common after first infusion; prophylaxis with acetaminophen or ibuprofen may be considered. Avoid co-administration with other nephrotoxic drugs. Osteonecrosis of the jaw risk with dental procedures; consider dental exam before start. Atypical femur fractures reported with prolonged use; evaluate for thigh/groin pain. Not for use in pregnancy; effective contraception needed. |
| Patient Advice | This medication is given as an intravenous infusion over at least 15 minutes. You may experience flu-like symptoms (fever, muscle aches) for a few days after the first dose; over-the-counter pain relievers can help. · You need to take calcium and vitamin D supplements as directed to prevent low blood calcium levels. · Contact your doctor immediately if you develop jaw pain, swelling, or numbness, especially after dental work, or if you have severe bone, joint, or muscle pain. · Maintain good oral hygiene and have regular dental check-ups; inform your dentist you are taking this drug before any procedures. · Drink plenty of water before and after the infusion to stay hydrated and reduce kidney strain. · Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. |